Trials / Recruiting
RecruitingNCT06370065
Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients
Efficacy and Safety of Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the efficacy and safety of Serplulimab combined with bevacizumab biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HAIC+Serplulimab（HLX10）+ Bevacizumab Biosimilar（HLX04） | PD-1 inhibitor |
Timeline
- Start date
- 2023-04-27
- Primary completion
- 2024-06-30
- Completion
- 2024-12-31
- First posted
- 2024-04-17
- Last updated
- 2024-04-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06370065. Inclusion in this directory is not an endorsement.